Oklahoma Heart Hospital Announces is Clinical Research Study Sit for Investigational Heart Failure Device

The Heart Failure Institute at Oklahoma Heart Hospital has been chosen as a site for the PEERLESS-HF (Prospective Evaluation of Elastic Restraint to LESSen the effects of Heart Failure) clinical research study. 

Dr. Philip Adamson, Medical Director of the Heart Failure Institute at Oklahoma Heart Hospital, will be principal investigator. Paracor Medical, Inc., of Sunnyvale, CA, is the sponsor of the clinical research study to evaluate its HeartNet™ therapy. 

What is HeartNet?

The HeartNet implant is delivered in a less-invasive surgical produced that can typically be completed in less than 90 minutes.  This elastic device provides continuous support to the walls of the heart’s pumping chambers, the ventricles.  It is the intent of HeartNet to stop or control further enlargement of the heart and alleviate the symptoms of advanced heart failure, which can include extreme fatigue, swelling in the extremities and shortness of breath.

The PEERLESS-HF clinical research study investigates the HeartNet therapy as compared to a control group of patients who continue optimal treatment with currently indicated therapies. 

Who Can Participate:

Those who might be interested in participating in the study for the HeartNet investigational device must be from 18 to 74 years of age, have moderate heart failure, be on heart failrure medications, have had heart failure for more than six months, have not had nor are considering a heart bypass procedure, and must not have severe kidney disease.  Additional creitera exist.  Only a clinical research study staff member can make the determination for eligibility to participate in this study. 

For more information or to determine eligibility for participation, please call 1-866-344-0628.